2-(4-methoxyphenyl)malondialdehyde | 53868-40-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-methoxyphenyl)malondialdehyde
• 英文别名: 2-(4-methoxyphenyl)-3-malonaldehyde；(2Z)-3-hydroxy-2-(4-methoxyphenyl)prop-2-enal；(Z)-3-hydroxy-2-(4-methoxyphenyl)prop-2-enal
• CAS: 53868-40-9
• 化学式: C₁₀H₁₀O₃
• 分子量: 178.188
• InChiKey: WASQXFIYEDZPDK-RMKNXTFCSA-N

物化性质

• 熔点：
  137-143 °C
• 沸点：
  270.41°C (rough estimate)
• 密度：
  1.1601 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi,C
• 安全说明：
  S25,S36/37/39,S45
• 危险类别码：
  R22,R34
• 海关编码：
  2912499000

反应信息

• 作为反应物：
  描述：

  2-(4-methoxyphenyl)malondialdehyde 在 2,4,6-三甲基吡啶 、 溶剂黄146 、 lithium iodide 作用下， 以 乙醇 为溶剂， 生成 4-(3-Phenyl-pyrazolo[1,5-a]pyrimidin-6-yl)-phenol
  参考文献：
  名称：

  Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics

  摘要：

  We have introduced solubilizing functionality to a 3,6-disubstituted pyrazolo[1,5-a]pyrimidine series of KDR kinase inhibitors to improve the physical properties of these compounds. The addition of a basic side-chain to the 6-aryl ring, introduction of 3-pyridyl groups, and most significantly, incorporation of a 4-pyridinonyl substituent at the 6-position of the core are modifications that maintain and often enhance the intrinsic potency of this class of inhibitors. Moreover, the improvements in physical properties result in marked increases in cellular activity and more favorable pharmacokinetics in rats. The synthesis and SAR of these compounds are described.(C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00827-2

文献信息

• Heterocyclic Compounds as Pesticides
  申请人：BRETSCHNEIDER Thomas

  公开号：US20110166143A1

  公开（公告）日：2011-07-07

  The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.

  本申请涉及使用杂环化合物来控制动物害虫，包括节肢动物，特别是昆虫，此外还涉及新型杂环化合物及其制备方法。
• Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-a]pyrimidines: A New Class of KDR Kinase Inhibitors
  作者：Mark E. Fraley、William F. Hoffman、Robert S. Rubino、Randall W. Hungate、Andrew J. Tebben、Ruth Z. Rutledge、Rosemary C. McFall、William R. Huckle、Richard L. Kendall、Kathleen E. Coll、Kenneth A. Thomas

  DOI：10.1016/s0960-894x(02)00525-5

  日期：2002.10

  synthesized and evaluated the activity of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines as a new class of KDR kinase inhibitors. Starting with screening lead 1, potency against isolated KDR was fully optimized with 3-thienyl and 4-methoxyphenyl substituents at the 6- and 3-positions (3g, KDR IC(50)=19 nM), respectively. The synthesis and SAR of these compounds are described.

  我们已经合成并评估了3,6-二取代的吡唑并[1,5-a]嘧啶作为一类新的KDR激酶抑制剂的活性。从筛选铅1开始，分别在6位和3位（3g，KDR IC（50）= 19 nM）处使用3-噻吩基和4-甲氧基苯基取代基完全优化了对分离的KDR的效力。描述了这些化合物的合成和SAR。
• Beta3 adrenergic receptor agonists and uses thereof
  申请人：Pfizer Inc.

  公开号：US20030203913A1

  公开（公告）日：2003-10-30

  The instant invention provides &bgr; 3 adrenergic receptor agonists of structural Formula (I), 1 the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr; 3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供结构式（I）的&bgr;3肾上腺素受体激动剂，其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐，其中Ar、R、R1、R2、R3、R4、R5、R6、R7、R8、X和Y如所述。本发明还提供在制备式（I）化合物中有用的中间体，以及式（I）化合物的组合物，其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐与抗肥胖剂的组合物；以及包括式（I）化合物、其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐，或包括式（I）化合物、其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐和抗肥胖剂的药物组合物。本发明还提供治疗哺乳动物&bgr;3肾上腺素受体介导的疾病、病况或障碍的方法，该方法包括向哺乳动物施用有效量的式（I）化合物、其立体异构体或前药，或其药物组合物；或者是式（I）化合物、其药学上可接受的盐、立体异构体或前药的组合物和抗肥胖剂，或其药物组合物的组合物。
• Bita3 adrenergic receptor agonists and uses thereof
  申请人：——

  公开号：US20020052392A1

  公开（公告）日：2002-05-02

  The instant invention provides &bgr; 3 adrenergic receptor agonists of structural Formula (I), 1 the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr; 3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供了结构式(I)的&bgr;3肾上腺素受体激动剂，其立体异构体和前药物，以及化合物、立体异构体和前药物的药学上可接受的盐，其中Ar、R、R1、R2、R3、R4、R5、R6、R7、R8、X和Y的定义如本文所述。本发明还提供了制备式(I)化合物的中间体，以及式(I)化合物、其立体异构体和前药物、药学上可接受的盐与抗肥胖剂的组合物；包括式(I)化合物、其立体异构体和前药物、药学上可接受的盐、或包括式(I)化合物、其立体异构体和前药物、药学上可接受的盐和抗肥胖剂的药物组合物的制药组合物；以及治疗哺乳动物的&bgr;3肾上腺素受体介导的疾病、病状或障碍的方法，该方法包括向哺乳动物投给式(I)化合物、其立体异构体或前药物的有效量，或其药物组合物；或者是式(I)化合物、其药学上可接受的盐、立体异构体或前药物和抗肥胖剂的组合物，或其药物组合物。
• &bgr;3 adrenergic receptor agonists and uses thereof
  申请人：Pfizer Inc.

  公开号：US06566377B2

  公开（公告）日：2003-05-20

  The instant invention provides &bgr;3 adrenergic receptor agonists of structural Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R1, R2, R3, R4, R5, R6, R7, R8, X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr;3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供了结构式（I）的β3肾上腺素受体激动剂，其立体异构体和前药，以及化合物的药物可接受的盐，立体异构体和前药的药物可接受的盐，其中Ar，R，R1，R2，R3，R4，R5，R6，R7，R8，X和Y如本文所定义。该发明还提供了在制备式（I）化合物中有用的中间体，与抗肥胖药物的式（I）化合物的组合，立体异构体和前药，以及化合物的药物可接受的盐，立体异构体和前药，以及包括式（I）的化合物的药物组合的制药组合物，立体异构体和前药，以及化合物的药物可接受的盐，立体异构体和前药，以及抗肥胖药物；以及治疗哺乳动物中β3肾上腺素受体介导的疾病，状况或障碍的方法，其中方法包括向哺乳动物施用式（I）化合物，其立体异构体或前药的有效量，或其药物组合物；或者是式（I）化合物，其药物可接受的盐，立体异构体或前药，以及抗肥胖药物的组合，或其药物组合物。